Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Number 6—June 2025
Research
Long-Term Clinical Outcomes of Adults Hospitalized for COVID-19 Pneumonia
, Alejandra Benitez, James A. McKinnell, Reena Shah, Michael Waters, Bradley D. Hunter, Robert Jeanfreau, Larry Tsai, Margaret Neighbors, Ben Trzaskoma, Rita de Cassia Castro, and Fang Cai
Table 1
Proportion of participants with lung texture abnormalities on HRCT scan in LOPAC study of long-term clinical outcomes of adults hospitalized for COVID-19 pneumonia*
| HRCT characteristics | No. (%) participants |
|
|---|---|---|
| LOPAC study, baseline | LOPAC study, month 12 | |
| Participants with >1 lung texture abnormality | 91 (52.6) | 56 (32.4) |
| Ground-glass opacification | 86 (49.7) | 51 (29.5) |
| Reticular pattern | 15 (8.7) | 10 (5.8) |
| Bronchiectasis | 12 (6.9) | 7 (4.0) |
| Hyperlucency† | 2 (1.2) | 2 (1.2) |
| Honeycombing |
0 |
0 |
| Participants with no lung texture abnormality‡ | 71 (41.0) | 62 (35.8) |
| Participants with missing data | 11 (6.4) | 55 (31.8) |
*Total number of participants enrolled in the LOPAC study was 173. HRCT, high-resolution computed tomography; LOPAC, Long-Term Outcomes Post Acute COVID-19. †Radiographic evidence of hyperlucency was assessed as unknown in 1 participant’s baseline and month 12 HRCT images. This participant was considered to have radiographic evidence of hyperlucency at baseline and month 12. ‡Participants were considered to have no lung texture abnormality if there was no radiologic evidence of ground-glass opacification, reticular pattern, bronchiectasis, hyperlucency, or honeycombing on HRCT scan.